1-(3,4-dimethoxyphenyl)-3-(4-fluorophenyl)prop-2-en-1-one

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 直链 1,3-二芳基丙烷
• 英文名称: 1-(3,4-dimethoxyphenyl)-3-(4-fluorophenyl)prop-2-en-1-one
• 英文别名: 1-(3,4-Dimethoxyphenyl)-3-(4-fluorophenyl) prop-2-en-1-one
• 化学式: C₁₇H₁₅FO₃
• 分子量: 286.303
• InChiKey: QTKUEXSSQYRHHA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.7
• 重原子数：
  21
• 可旋转键数：
  5
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  35.5
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  1-(3,4-dimethoxyphenyl)-3-(4-fluorophenyl)prop-2-en-1-one 在 溶剂黄146 作用下， 以 乙醇 、 水 为溶剂， 反应 24.0h， 生成 5-(4-fluorophenyl)-3-(3,4-dimethoxyphenyl)-1-(4-sulfamoylphenyl)-1H-pyrazole
  参考文献：
  名称：

  Synthesis of novel halogenated triarylpyrazoles as selective COX-2 inhibitors: Anti-inflammatory activity, histopatholgical profile and in-silico studies

  摘要：

  A novel series of halogenated triarylpyrazoles 12a-l was designed and synthesized. All target compounds showed good in vitro COX-2 inhibitory activity (IC₅₀ = 0.043-0.17 µM) over COX-1 (IC₅₀ = 7.8 - 15.4 µM) relative to celecoxib (COX-1/IC₅₀ = 9.87, COX-2/IC₅₀ = 0.055), with acceptable selectivity index values (SI = 50.6-253.1). Also, they displayed moderate to potent in vivo anti-inflammatory activity (% edema inhibition = 16.9-87.9) comparable to celecoxib (% edema inhibition = 46.6-72.1) as standard drug. Three fluorinated pyrazoles 12a, 12g and 12j, exhibited superior anti-inflammatory activity at all time intervals (% edema inhibition = 42.1-87.9) with better gastric profile (UI = 1.25-2.5) than the traditional NSAID; indomethacin (UI = 14) and were close to the selective COX-2 inhibitor; celecoxib (UI = 1.75). In-silico docking and ADME studies of 12a, 12g and 12j supported the obtained biological data and pointed out their potential use for the development of bio-available, safe and potent anti-inflammatory drugs.

  DOI：

  10.1016/j.bioorg.2020.104418
• 作为产物：
  描述：

  对氟苯甲醛 、 3,4-二甲氧基苯乙酮 在 sodium hydroxide 作用下， 以 甲醇 为溶剂， 生成 1-(3,4-dimethoxyphenyl)-3-(4-fluorophenyl)prop-2-en-1-one
  参考文献：
  名称：

  多晶型供体-受体取代查耳酮：用于光限幅应用的结构、光谱、介电和非线性光学特性

  摘要：

  在此，我们报告了氟化多晶型非线性光学 (NLO) 材料 1-(3,4-二甲氧基苯基)-3-(4-氟苯基) prop-2-en-1-one (缩写为 PDPFO）基于反饱和吸收。光学透明 PDPFO 单晶的 FTIR 研究证实了各种官能团的存在。PDPFO 在可见光波长范围内是光学透明的。开孔 Z 扫描技术显示出依赖于强度的非线性吸收。归一化透射率随输入强度的降低表明波长 532 nm 处的光学限制行为。激发态吸收截面值 ( \({\sigma }_{ex}=\) 1.72 × 10 –16 cm 2) 远大于基态吸收截面值\(({\sigma }_{g}=\) 2.49 × 10 –22 cm 2 )，表明光学限制现象是由 RSA 引起的。

  DOI：

  10.1007/s11696-021-01705-9

文献信息

• Design, synthesis, and biological evaluation of polyphenols with 4,6-diphenylpyrimidin-2-amine derivatives for inhibition of Aurora kinase A
  作者：Young Han Lee、Jihyun Park、Seunghyun Ahn、Youngshim Lee、Junho Lee、Soon Young Shin、Dongsoo Koh、Yoongho Lim

  DOI：10.1007/s40199-019-00272-5

  日期：2019.6

  cytotoxicities against cancer cells, quantitative structure-activity relationships (QSAR) were calculated. Biological activities were determined by flow cytometry for cell cycle analysis and by immunoblot analysis for the detection of Aurora kinase A (AURKA) activity. Because 2-(2-Amino-6-(2,4-dimethoxyphenyl)pyrimidin-4-yl) phenol (derivative 12) selectively inhibited AURKA activity from the kinome assay

  背景技术几种4，6-二芳基嘧啶-2-胺衍生物显示出抗癌特性。但是，它们的作用方式尚未完全表征。为了开发有效的抗癌化学治疗剂，我们设计并合成了25个含有胍基部分的4,6-二苯基嘧啶-2-胺衍生物。方法进行了长期克隆存活试验以筛选抗癌化合物。为了得出对癌细胞具有良好细胞毒性的结构条件，计算了定量构效关系（QSAR）。通过流式细胞术测定生物活性以进行细胞周期分析，并通过免疫印迹分析测定Aurora激酶A（AURKA）活性。由于2-（2-氨基-6-（2,4-二甲氧基苯基）嘧啶-4-基）苯酚（衍生物12）通过kinome分析选择性抑制AURKA活性，在计算机对接实验中进行了阐明衍生物12和AURKA之间的分子结合模式。结果药效基团是基于QSAR计算得出的。衍生物12抑制了HCT116人结肠癌细胞在Thr283处的AURKA活性并降低了AURKA的磷酸化。衍生物12引起细胞周期G2 / M期的积累，并
• AMINOAMIDES AS OREXIN ANTAGONISTS
  申请人：Gobbi Luca

  公开号：US20080221166A1

  公开（公告）日：2008-09-11

  The present invention relates to compounds of formula I wherein Ar 1 , Ar 2 , Ar 3 , n, and R 1 to R 8 are as defined herein and to pharmaceutically suitable acid addition salts, optically pure enantiomers, racemates or diastereomeric mixtures thereof. These compounds are orexin receptor antagonists and may be useful in the treatment of disorders, in which orexin pathways are involved, like sleep disorders.

  本发明涉及具有以下结构的化合物（I）其中Ar1，Ar2，Ar3，n和R1至R8的定义如本文所述，并且涉及其药用适宜的酸加盐、光学纯对映体、混合物或二对映异构体。这些化合物是促进睡眠的受体拮抗剂，可能在涉及促进睡眠途径的疾病治疗中有用，如睡眠障碍。
• US7829563B2
  申请人：——

  公开号：US7829563B2

  公开（公告）日：2010-11-09
• Polymorphic donor–acceptor substituted chalcone: structural, spectral, dielectric and nonlinear optical properties for optical limiting applications
  作者：S. Raghavendra、C. S. Chidan Kumar、D. J. Madhu Kumar、Mohammed Al-Ghorbani、Ali Alsalme、C. K. Quah、P. V. Raghavendra、Felcy Jyothi Serrao、S. M. Dharmaprakash

  DOI：10.1007/s11696-021-01705-9

  日期：——

  report the third-order nonlinear absorption and optical limiting property of fluorinated polymorphic nonlinear optical (NLO) material 1-(3,4-dimethoxyphenyl)-3-(4-fluorophenyl) prop-2-en-1-one (abbreviated as PDPFO) based on reverse saturable absorption. The FTIR studies of optically transparent PDPFO single crystals confirm the presence of various functional groups. PDPFO is optically transparent

  在此，我们报告了氟化多晶型非线性光学 (NLO) 材料 1-(3,4-二甲氧基苯基)-3-(4-氟苯基) prop-2-en-1-one (缩写为 PDPFO）基于反饱和吸收。光学透明 PDPFO 单晶的 FTIR 研究证实了各种官能团的存在。PDPFO 在可见光波长范围内是光学透明的。开孔 Z 扫描技术显示出依赖于强度的非线性吸收。归一化透射率随输入强度的降低表明波长 532 nm 处的光学限制行为。激发态吸收截面值 ( \(\sigma }_ex}=\) 1.72 × 10 –16 cm 2) 远大于基态吸收截面值\((\sigma }_g}=\) 2.49 × 10 –22 cm 2 )，表明光学限制现象是由 RSA 引起的。
• Synthesis of novel halogenated triarylpyrazoles as selective COX-2 inhibitors: Anti-inflammatory activity, histopatholgical profile and in-silico studies
  作者：Khaled R.A. Abdellatif、Eman K.A. Abdelall、Madlen B. Labib、Wael A.A. Fadaly、Taha H. Zidan

  DOI：10.1016/j.bioorg.2020.104418

  日期：2020.12

  A novel series of halogenated triarylpyrazoles 12a-l was designed and synthesized. All target compounds showed good in vitro COX-2 inhibitory activity (IC₅₀ = 0.043-0.17 µM) over COX-1 (IC₅₀ = 7.8 - 15.4 µM) relative to celecoxib (COX-1/IC₅₀ = 9.87, COX-2/IC₅₀ = 0.055), with acceptable selectivity index values (SI = 50.6-253.1). Also, they displayed moderate to potent in vivo anti-inflammatory activity (% edema inhibition = 16.9-87.9) comparable to celecoxib (% edema inhibition = 46.6-72.1) as standard drug. Three fluorinated pyrazoles 12a, 12g and 12j, exhibited superior anti-inflammatory activity at all time intervals (% edema inhibition = 42.1-87.9) with better gastric profile (UI = 1.25-2.5) than the traditional NSAID; indomethacin (UI = 14) and were close to the selective COX-2 inhibitor; celecoxib (UI = 1.75). In-silico docking and ADME studies of 12a, 12g and 12j supported the obtained biological data and pointed out their potential use for the development of bio-available, safe and potent anti-inflammatory drugs.